SalioGen Therapeutics Announces Closing of $20 Million Series A Financing to Support Advancing...

SalioGen Therapeutics Announces Closing of $20 Million Series A Financing to Support Advancing a Novel Genome Engineering Platform for Non-Viral Gene Therapy

"Introducing a mammal-derived genome engineering enzyme for next-generation gene and cell therapy

Financing to fund SalioGen’s pipeline in genetic diseases, based on proprietary EDIT ‘gene coding’ platform to advance durable, safe and affordable non-viral gene therapies

Financing concurrent with strengthening of board of directors and scientific advisory board..."

030221 SalioGen Therapeutics Announces C

.

Download • 94KB